2012 Scientific Report - Queensland Children's Medical Research ...
2012 Scientific Report - Queensland Children's Medical Research ...
2012 Scientific Report - Queensland Children's Medical Research ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Research</strong> Grants and Contracts<br />
Years Grant Agency Chief<br />
Investigators<br />
2010- QCMRI/ Children’s A/Prof. A<br />
2015 Health Foundation Hallahan<br />
<strong>Queensland</strong><br />
Title<br />
Tumour Bank - Infrastructure<br />
Funding<br />
Amount<br />
$401,911<br />
<strong>2012</strong>-<br />
2013<br />
The BrainChild<br />
Foundation<br />
Dr. W Ingram<br />
Towards Better Outcomes For<br />
Children With Brain Tumours –<br />
Advancement Of Multiple <strong>Research</strong><br />
Studies Using Banked Specimens<br />
$25,000<br />
<strong>2012</strong>-<br />
2016<br />
NHMRC Dr A Moore The role of Survivin and XIAP (Xlinked<br />
inhibitor of apoptosis<br />
protein) as biomarkers and<br />
therapeutic targets in paediatric<br />
acute myeloid leukamia<br />
$248,424<br />
<strong>2012</strong>-<br />
2016<br />
Children’s Health<br />
Foundation<br />
<strong>Queensland</strong> / QCMRI<br />
Dr A Moore<br />
A study to assess the mechanisms<br />
of cell death in acute myeloid<br />
leukaemia.<br />
$506,615<br />
<strong>2012</strong> Pfizer Australia Dr A Moore The role of Survivin and XIAP (Xlinked<br />
inhibitor of apoptosis<br />
protein) as biomarkers and<br />
therapeutic targets in paediatric<br />
acute myeloid leukamia<br />
<strong>2012</strong> ANZ Trustees Dr A Moore The role of Survivin and XIAP (Xlinked<br />
inhibitor of apoptosis<br />
protein) as biomarkers and<br />
therapeutic targets in paediatric<br />
acute myeloid leukamia<br />
$50,000<br />
$50,000<br />
Publications<br />
Peer Reviewed Manuscripts<br />
1. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M,<br />
Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A,<br />
Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J. Optimization of<br />
imidazo [4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora<br />
kinase inhibitor as an orally bioavailable preclinical development candidate for the<br />
treatment of acute myeloid leukemia. J Med Chem<strong>2012</strong>; 55: 8721-34<br />
QCMRI <strong>Scientific</strong> <strong>Report</strong> <strong>2012</strong> 7